Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kura Oncology (KURA)

Kura Oncology (KURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,241,113
  • Shares Outstanding, K 77,764
  • Annual Sales, $ 0 K
  • Annual Income, $ -152,630 K
  • EBIT $ -217 M
  • EBITDA $ -226 M
  • 60-Month Beta 0.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.90

Options Overview Details

View History
  • Implied Volatility 70.88% ( +0.17%)
  • Historical Volatility 41.76%
  • IV Percentile 52%
  • IV Rank 36.55%
  • IV High 154.33% on 01/19/24
  • IV Low 22.80% on 09/11/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 33
  • Put/Call OI Ratio 1.15
  • Today's Open Interest 693
  • Open Int (30-Day) 727

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.65
  • Number of Estimates 8
  • High Estimate -0.52
  • Low Estimate -0.75
  • Prior Year -0.55
  • Growth Rate Est. (year over year) -18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.42 +3.18%
on 11/20/24
19.73 -19.35%
on 11/12/24
-2.09 (-11.61%)
since 10/18/24
3-Month
15.42 +3.18%
on 11/20/24
21.57 -26.24%
on 09/03/24
-4.17 (-20.77%)
since 08/20/24
52-Week
9.06 +75.61%
on 11/28/23
24.17 -34.17%
on 03/11/24
+6.36 (+66.60%)
since 11/20/23

Most Recent Stories

More News
Kura Oncology and Kyowa Kirin Announce Strategic Collaboration for Ziftomenib Development with $330 Million Upfront Payment

Kura and Kyowa Kirin collaborate to develop ziftomenib for AML, providing substantial milestone payments and joint commercialization efforts.Quiver AI SummaryKura Oncology and Kyowa Kirin have announced...

KURA : 15.91 (-0.31%)
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

KURA : 15.91 (-0.31%)
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and...

KURA : 15.91 (-0.31%)
Kura Oncology: Q3 Earnings Snapshot

Kura Oncology: Q3 Earnings Snapshot

KURA : 15.91 (-0.31%)
Kura Oncology Reports Third Quarter 2024 Financial Results

KURA : 15.91 (-0.31%)
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

KURA : 15.91 (-0.31%)
Kura Oncology to Report Third Quarter 2024 Financial Results

KURA : 15.91 (-0.31%)
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

KURA : 15.91 (-0.31%)
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

KURA : 15.91 (-0.31%)
Kura Oncology: Q2 Earnings Snapshot

Kura Oncology: Q2 Earnings Snapshot

KURA : 15.91 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

3rd Resistance Point 16.86
2nd Resistance Point 16.48
1st Resistance Point 16.19
Last Price 15.91
1st Support Level 15.52
2nd Support Level 15.14
3rd Support Level 14.85

See More

52-Week High 24.17
Fibonacci 61.8% 18.40
Fibonacci 50% 16.61
Last Price 15.91
Fibonacci 38.2% 14.83
52-Week Low 9.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar